medtronic minimed 760g

1. Minimed Medtronic 760G optimizes glucose control in patients with type 1 diabetes mellitus Evaluated 59 T1D patients, comparing automatic (auto) vs manual modes over intervals from 1 month to over 6 months. Results: Significant improvements in Time in Range (TIR), glucose variability, HbA1c, and reduced Time Below Range (TBR < 54 mg/dL). No severe hypoglycemia or ketoacidosis was recorded. PubMed 2. Safety, Metabolic and Psychological Outcomes of Medtronic MiniMed 760G in Children, Adolescents and Young Adults: A Systematic Review Review of 31 studies in individuals under 25 years with T1D. Metabolic outcomes: HbA1c dropped to around 7%; TIR of 75–80%; TBR and TAR within recommended targets. Safety: No severe hypoglycemia (SH) or diabetic ketoacidosis (DKA) in most studies. Psychological outcomes: Improvements in sleep quality, treatment satisfaction, and reduction in emotional burden for patients and caregivers. PubMed NCBI 3. Long-term Real‑World Use in Pediatric Population A real-world study of 111 children/adolescents over up to 24 months: After switching to auto mode, TIR rose from ~67% to ~76%; TAR levels dropped; variability and mean glucose improved significantly. Improvements sustained throughout 24 months. Better outcomes observed when using optimal settings (Active Insulin Time (AIT) of 2 h and SmarGuard target of 100 mg/dL).